{"id":"tigan","safety":{"commonSideEffects":[{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":{"setId":"7da90678-b229-4ad6-9193-2b8a3e9ba695","title":"TIGAN (TRIMETHOBENZAMIDE HYDROCHLORIDE) INJECTION [PAR HEALTH USA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trimethobenzamide is an antiemetic that acts as a dopamine antagonist, primarily affecting the chemoreceptor trigger zone in the brain. By blocking dopamine receptors in this area, it suppresses the vomiting reflex and reduces nausea. It has weaker antihistamine and anticholinergic properties compared to other antiemetics.","oneSentence":"Tigan (trimethobenzamide) blocks dopamine receptors in the chemoreceptor trigger zone to prevent nausea and vomiting.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:37.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Nausea and vomiting"},{"name":"Postoperative nausea and vomiting"}]},"trialDetails":[{"nctId":"NCT01770145","phase":"PHASE4","title":"Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)","status":"COMPLETED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2012-12","conditions":"Parkinson's Disease, Motor Symptoms, Akinesia","enrollment":127},{"nctId":"NCT00489255","phase":"PHASE4","title":"Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2007-05","conditions":"Parkinson's Disease","enrollment":117}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tigan®","genericName":"Tigan®","companyName":"Ipsen","companyId":"ipsen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tigan (trimethobenzamide) blocks dopamine receptors in the chemoreceptor trigger zone to prevent nausea and vomiting. Used for Nausea and vomiting, Postoperative nausea and vomiting.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}